Welcome to Day Lab
The Day lab is interested in genetic heart muscle diseases. Our research program integrates translational and clinical science, with a primary focus on hypertrophic cardiomyopathy. We want to understand the full spectrum of disease evolution and progression, from the primary effects of sarcomere gene mutations in cardiac muscle cells to the phenotypic expression and predictors of adverse outcomes in patients.
Research News
New Grants
R01 - Risk Alleles in Protein Quality Control Genes as Modifiers of Hypertrophic Cardiomyopathy (NHLBI)
Chris McAllister received an AHA Predoctoral Fellowship Award for his proposal Gene replacement therapy for myosin binding protein C in hypertrophic cardiomyopathy. Congratulations!
Dr. Day is the PI of Penn's recently funded American Heart Association Institutional Summer Undergraduate Research Award!
R01- Missense Variants In Myosin Binding Protein C That Cause Hypertrophic Cardiomyopathy; National Heart, Lung, And Blood Institute (NHLBI)
R61/R33 - Sglt2-Inhibitors In Patients With Hypertrophic Cardiomyopathy; National Heart, Lung, And Blood Institute (NHLBI)
Preclinical Studies Of Sotagliflozin In Hypertrophic Cardiomyopathy; Lexicon Pharmaceuticals, Inc.
Individual Awards and Congratulations
Chris McAllister passed his prelim exam! Congrats!
Chris McAllister was awarded a spot on the Penn Muscle Institute T32.
Andrea Thompson has received her K08!
Patrick Moore, from the University of Alabama, was awarded an AHA Summer Fellowship to spend the summer doing research in Day Lab!
Graham Branscom was accepted into the University Scholars Program. Congrats!
Marcus Wagner was awarded a Brody Postdoctoral Fellowship.
Presentations and Conferences
Chris McAllister and Marcus Wagner both presented abstracts at BCVS Boston!
Marcus Wagner was invited to present an abstract at "Best of AHA Subspecialty Conference".
Recent Manuscripts
Previs MJ, O'Leary TS, Morley MP, Palmer B, LeWinter M, Yob J, Pagani FD, Petucci C, Kim MS, Margulies KB, Arany Z, Delly DP, Day SM: Defects in the Proteome and Metabolome in Human Hypertrophic Cardiomyopathy. Circulation HF 15(6): e009521, May 2022.
Herrera JJ, Pifer K, Louzon S, Leander D, Fiehn O, Day SM, Miller RA, Garratt M: Early or Late-life treatment with acarbose or rapamycin improves physical performance and affects cardiac structure in aging mice. J Gerontology A Biol Sci Med Sci 78(3): 397-406, March 2023.
Lampert R, Ackerman MJ, Marino BS, Burg M, Ainsworth B, Salberg L, Tome Esteban M, Ho CY, Abraham R, Balaji S, Barth C, Berul C, Bos M, Cannom D, Choudhury L, Concannon M, Cooper R, Czosek RJ, Dubin AM, Dziura J, Eidem B, Emery MS, Estes M, Etheridge SP, Geske JB, Gray B, Hall K, Harmon KG, James CA, Lal AK, Law IH, Li F, Link MS, McKenna WJ, Molossi S, Olshansky B, Ommen SR, Saarel EV, Saberi S, Simone L, Tomaselli G, Ware JS, Zipes DP, Day SM, for the LIVE Consortium: Vigorous Exercise in Patients with Hypertrophic Cardiomyopathy. JAMA Cardiology 8(6): 595-605, June 2023
Thompson AD, Wagner MJ, Rodriguez J, Malhotra A, Roest SV, Lilienthal U, Shao H, Yob JM, Prosser BL, Helms AS, Gestwicki JE, Ginsburg D, Day SM. : An unbiased screen identified the Hsp70-BAG3 complex as a regulator of myosin binding protein C3 stability. JACC BTS Page: in press, 2023.
Day SM, Tardiff JC, Ostap EM: Myosin modulators: Emerging approaches for the treatment of cardiomyopathies and heart failure. JCI 132(5): e148557, March 2022.
Hastings MH, Herrera JJ, Guseh S, Atlason B, Houstis NE, Kadir AA, Le H, Sheffield C, Singh AP, Roh J, Day SM, Rosenzweig A: Animal Models of Exercise from Rodents to Pythons. Circulation Research 130(12): 1994-2014, June 2022.